Track market-moving stories before they get noisy

Burlington Stores (BURL - Free Report) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $1.6 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +13.42%. A quarter ago, it was expected that this discount retailer would post earnings of $4.7 per share when it actually produced earnings of $4.89, delivering a surprise of +4.04%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Burlington Stores, which belongs to the Zacks Retail - Discount Stores industry, posted revenues of $2.86 billion for the quarter ended April 2026, surpassing the Zacks Consensus Estimate by 1.83%. This compares to year-ago revenues of $2.5 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Burlington Stores shares have added about 12.9% since the beginning of the year versus the S&P 500's gain of 9.9%.

What's Next for Burlington Stores?While Burlington Stores has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Burlington Stores was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.89 on $2.96 billion in revenues for the coming quarter and $11.30 on $12.71 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Discount Stores is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Dollar General (DG - Free Report) , another stock in the same industry, has yet to report results for the quarter ended April 2026. The results are expected to be released on June 2.

This discount retailer is expected to post quarterly earnings of $1.89 per share in its upcoming report, which represents a year-over-year change of +6.2%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level.

Dollar General's revenues are expected to be $10.83 billion, up 3.8% from the year-ago quarter.

Burlington Stores, Inc. (NYSE:BURL) reported Thursday that first-quarter net income rose to $115 million. The off-price retailer earned $1.79 per diluted share, up from $1.58 per diluted share a year earlier.

• Burlington Stores stock is showing notable weakness. Why is BURL stock falling?

Q1 Results Beat EstimatesAdjusted EPS was $2.10, beating the $1.78 estimate. Sales were $2.856 billion, above the $2.799 billion estimate. Total sales rose 14% to $2.852 billion, while comparable store sales increased 6%.

"We are raising our full-year Fiscal 2026 sales and earnings guidance, passing through the entire upside from the first quarter to the full year. Our updated guidance is for comp store sales to increase 2% to 4%, and for EPS growth of 13% to 16%. These numbers underscore our ability to convert incremental comp sales into very strong earnings growth,” stated CEO Michael O'Sullivan.

Margins Expand On Sales StrengthGross margin expanded 30 basis points to 44.1%, reflecting gains in merchandise margin and lower freight expense as a percentage of net sales.

SG&A was flat at 34.7% of net sales. Adjusted SG&A rose to 26.8% of net sales from 26.6% a year earlier, excluding expenses tied to bankruptcy-acquired leases.

Profitability improved in the quarter, with adjusted EBITDA rising to $284 million from $244 million. Adjusted EBIT increased to $179 million from $152 million, with adjusted EBIT margin expanding 20 basis points.

Inventory and LiquidityMerchandise inventories increased 10% to $1.444 billion, driven by 127 net new stores and an 11% comparable-store inventory increase. Reserve inventory fell to 41% of total inventory from 48% a year earlier.

Burlington ended the quarter with $747.4 million in cash and $1.689 billion in liquidity, including $942 million of ABL facility availability.

Net cash provided by operating activities was $61.5 million, compared with net cash used in operating activities of $28.9 million a year earlier. Cash paid for property and equipment was $288.7 million.

Outlook RaisedBurlington raised its fiscal 2026 adjusted EPS outlook to $11.45 to $11.80 from $10.95 to $11.45. The outlook compares with the $11.56 estimate.

The company expects total sales to rise 9% to 11%, with comparable store sales up 2% to 4%.

Fiscal 2026 adjusted EBIT margin to expand 10 to 30 basis points, capital expenditures net of landlord allowances of about $875 million, and about 115 net new store openings.

For the second quarter, Burlington expects adjusted EPS of $2.05 to $2.20, above the $1.95 estimate.

It sees total sales rising 10% to 12%, comparable-store sales increasing 1% to 3%, and adjusted EBIT margin expanding by 30 to 60 basis points.

The company also cited import risks, including tax and trade policies, tariffs, and government regulations, among forward-looking risks.

BURL Price Action: Burlington Stores shares were trading 7.53% lower at $301.40 at publication on Thursday.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Ross Stores Earnings Beat Sends Stock To New HighsBurlington Stores NYSE: BURL reported stronger-than-expected fiscal first-quarter results, with executives saying the off-price retailer benefited from broad-based comp growth, better markdown execution and supply chain productivity.

Chief Executive Officer Michael O'Sullivan said the company delivered a 26% increase in adjusted earnings per share, marking what he called Burlington's 14th consecutive quarter of double-digit earnings growth. Total sales rose 14% in the quarter, while comparable store sales increased 6%, above the company's prior guidance range of 2% to 4%.

Get Burlington Stores alerts:

Wall Street Loves TJX, But Is the Stock Still a Good Deal for Investors?"This track record demonstrates our ability to consistently convert higher sales into margin expansion, thereby driving very strong earnings flow-through," O'Sullivan said.

Executive Vice President and Chief Financial Officer Kristin Wolfe said first-quarter adjusted EPS was $2.10, above Burlington's guidance range of $1.60 to $1.75. Adjusted EBIT margin was 6.3%, up 20 basis points from the prior year and ahead of guidance that had called for a 60- to 100-basis-point decline.

Comparable Sales Beat Guidance 3 ETFs That Could Benefit as Consumers Tighten Their BudgetsO'Sullivan said first-quarter comp trends were "broad-based across businesses and geographies," with particular strength in ladies' apparel, beauty and accessories. He also highlighted warm-weather categories, including shorts, short-sleeved tops, swimwear, sandals and sunglasses, which he said accounted for about 25% of first-quarter sales and posted double-digit comp growth.

The company attributed part of the strength to upgraded allocation and localization capabilities. O'Sullivan said Burlington historically had struggled with seasonal transitions, in part because of its legacy as an outerwear retailer, but newer systems allowed the company to make more precise allocation decisions.

"We know that we're never going to be able to control the weather, but we can get better at responding to it," O'Sullivan said during the question-and-answer session.

Wolfe said the Northeast and Midwest were the top-performing regions in the quarter, while the Southeast and West were in line with the chain and the Southwest trailed. She said the comp gain was driven by both higher transactions and a larger basket, with basket growth reflecting higher average unit retail.

Margins Improve Despite Expected Headwinds Burlington's gross margin rate was 44.1% in the first quarter, up 30 basis points from a year earlier. Wolfe said that included a 20-basis-point increase in merchandise margin and a 10-basis-point decrease in freight expenses. Product sourcing costs were $216 million, up from $197 million a year earlier, but decreased 30 basis points as a percentage of sales as the company continued supply chain productivity and cost-savings initiatives.

Wolfe said the company had entered the quarter expecting several margin headwinds, but stronger-than-anticipated sales, disciplined markdown execution and supply chain productivity more than offset those pressures. She also cited the quality of buys as a factor supporting merchandise margin performance.

Adjusted SG&A costs increased 20 basis points versus last year, which Wolfe said reflected factors including higher incentive compensation and marketing spend. The company ended the quarter with approximately $1.7 billion in total liquidity, including $747 million in cash and $942 million of availability on its asset-based lending facility, with no outstanding borrowings on the ABL. Burlington repurchased $81 million of common stock during the quarter and ended with $304 million remaining on its share repurchase authorization, which expires in May 2027.

Full-Year Outlook Raised Burlington raised its full-year fiscal 2026 outlook, passing through the entire first-quarter upside. The company now expects total sales to increase 9% to 11%, up from prior guidance of 8% to 10%. Comparable store sales are expected to rise 2% to 4%.

The company forecast adjusted EBIT margin expansion of 10 to 30 basis points for the full year and adjusted EPS of $11.45 to $11.80, representing growth of 13% to 16% versus fiscal 2025. The guidance excludes approximately $10 million of costs associated with bankruptcy-acquired leases, compared with $35 million in 2025.

For the second quarter, Burlington guided for comparable sales growth of 1% to 3% and total sales growth of 10% to 12%. The company expects operating margin expansion of 30 to 60 basis points and adjusted EPS of $2.05 to $2.20, compared with $1.72 in the year-ago quarter. Wolfe said May month-to-date sales were tracking at the high end of the comp guidance range, though comparisons become more difficult as the quarter progresses.

Wolfe said the second-quarter margin outlook assumes higher merchandise margin, driven by anticipated markdown favorability, modestly faster turns and a favorable shortage accrual rate compared with last year. Those gains are expected to be partially offset by modest freight pressure from higher fuel rates. She said the company recently locked in ocean and domestic contracts for the next year at favorable rates, though higher diesel prices from current projections could pose an incremental risk.

Store Growth and Productivity Remain Key Priorities Burlington opened 40 gross new stores in the first quarter, relocated six stores and closed four, resulting in 30 net new stores and a quarter-end store count of 1,242. For the full year, the company now expects 135 gross new stores and 115 net new stores, up from its prior outlook of 110 net new stores.

O'Sullivan said Burlington remains on track to exceed 1,500 stores by the end of 2028. Wolfe said the company is comfortable opening at least 110 net new stores in both 2027 and 2028 and continues to see new stores open at about $7 million in sales in their first full year, with payback in just under two years.

O'Sullivan also emphasized relocations and downsizes as important drivers of productivity. He said relocations typically deliver a sales lift of 5% to 10% as Burlington upgrades stores and moves into higher-traffic centers. The downsize program targets older stores where the company likes the location but considers the box oversized. Burlington downsized 20 stores in 2025 and expects about 30 this year, with typical projects cutting square footage in half and reducing occupancy costs by about 200 basis points on average.

O'Sullivan said Burlington's sales per selling square foot has increased from about $220 in 2019 to roughly $350 today. He said new stores, relocations and downsizes should continue to support occupancy leverage over time.

Executives Say Consumer Remains Resilient During the call, analysts asked about gas prices, inflation and broader retail trends. O'Sullivan said Burlington remains "bullish" about the year, particularly the back half, while acknowledging the company is "a little more wary" than it was in March because of higher gas prices and the potential impact on inflation.

O'Sullivan said the company has not yet seen a change in consumer behavior, adding that stores in lower-income trade areas continued to outperform the chain in the first quarter. Stores in higher-income areas still posted mid-single-digit comp growth, he said. Stores in high-Hispanic areas also posted mid-single-digit comp growth, broadly in line with the chain.

O'Sullivan said higher tax refunds contributed an estimated 1.5 to 2 percentage points to first-quarter comp growth. Excluding that benefit, he said, comp growth still would have been in the mid-single digits.

The CEO also said the supply of off-price merchandise is "excellent right now" and that tariffs have been less disruptive to pricing and supply than last year. Wolfe said Burlington has filed for tariff refunds, but the company has not included any potential benefit in its guidance because the amount and timing remain uncertain.

O'Sullivan said the broader retail environment continues to favor off-price retailers as consumers prioritize value. "The customer is voting for value, off-price is delivering that value," he said.

About Burlington Stores NYSE: BURLBurlington Stores, Inc is an American off-price retailer that sells apparel and home goods at discounted prices. The company's merchandise assortment includes clothing for women, men and children, plus baby products, footwear, accessories, beauty items, toys and home décor. Burlington's merchandising strategy focuses on offering branded and private-label goods at lower prices than traditional department stores by sourcing excess inventory, closeouts and opportunistic buys from manufacturers and other retailers.

The business traces its roots to the Burlington Coat Factory name established in the early 1970s and has since evolved into a broader off-price retailer that carries a wide range of seasonal and everyday merchandise.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Burlington Stores Right Now?Before you consider Burlington Stores, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burlington Stores wasn't on the list.

While Burlington Stores currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Burlington Stores, Inc. (BURL) Q1 2026 Earnings Call Transcript

Key Takeaways BURL topped Q1 earnings and revenue estimates as comparable store sales increased 6%.The gross margin expanded and the EBIT margin rose on merchandise gains and supply-chain productivity.Burlington Stores raised FY26 sales, EPS and net new store growth expectations. Burlington Stores, Inc. (BURL - Free Report) reported impressive first-quarter fiscal 2026 results, wherein revenues and earnings grew year over year. Also, the top and bottom lines surpassed the Zacks Consensus Estimate. The off-price retailer benefited from broad-based comparable sales growth, merchandise margin expansion and continued supply-chain productivity improvements, enabling the company to post its 14th consecutive quarter of double-digit earnings growth.

Management highlighted strong execution across merchandising, inventory management and store operations, with particular strength in ladies apparel, beauty and accessories. Burlington Stores also benefited from improved allocation and localization capabilities, which helped the company capitalize on warm-weather demand trends during the quarter.

Despite the strong performance and an increase in the fiscal 2026 guidance, investors reacted negatively to the results, sending shares down 7.9% following the announcement. The decline likely reflected elevated investor expectations heading into the release, as well as caution surrounding the company's modest fiscal second-quarter comparable sales guidance and broader consumer spending uncertainties.

More on Burlington Stores’ Q1 Financial ResultsBurlington Stores reported adjusted earnings of $2.01 per share, comfortably beating the Zacks Consensus Estimate of $1.77. Adjusted EPS increased 25.6% from $1.60 in the year-ago quarter.

Total revenues increased 14.1% year over year to $2.86 billion and exceeded the Zacks Consensus Estimate of $2.81 billion. Net sales rose 14% to $2.85 billion from $2.50 billion in the prior-year period.

Comparable store sales increased 6%, significantly ahead of management’s guidance of 2-4%. According to management, comps growth was broad-based across merchandise categories and geographic regions, reflecting healthy consumer demand and effective execution of Burlington Stores’ off-price model. Our model anticipated a 3.5% year-over year rise in comparable store sales for the fiscal first quarter.

Insight Into BURL’s MarginsThe gross margin expanded 30 basis points year over year to 44.1% in the first quarter of fiscal 2026. This also surpassed our estimate for gross margin of 43.5%. The improvement was driven by a 20-basis-point increase in the merchandise margin and a 10-basis-point reduction in freight expenses as a percentage of net sales.

Adjusted selling, general and administrative (SG&A) expenses increased 15.2% year over year to $771.3 million from $669.5 million in the first quarter of fiscal 2025. Adjusted SG&A, excluding expenses related to bankruptcy-acquired leases, represented 26.8% of net sales, up 20 basis points year over year. Notably, adjusted SG&A surpassed our estimate of 26.3% of net sales.

Product sourcing costs increased to $216 million from $197 million in the first quarter of fiscal 2025. However, as a percentage of sales, product sourcing costs declined by 30 basis points year over year, reflecting continued progress on supply-chain productivity initiatives and cost-saving programs across the distribution network. Such costs comprise the processing goods costs via the supply chain and buying expenses.

Adjusted EBIT increased to $179 million from $152 million in the first quarter of fiscal 2025. The adjusted EBIT margin expanded 20 basis points year over year to 6.3%, significantly exceeding management's original expectation for a margin decline of 60-100 basis points. According to management, the margin outperformance was primarily driven by higher merchandise margins, stronger sales leverage and continued supply-chain productivity gains.

Adjusted EBITDA increased to $284 million from $244 million in the prior-year quarter. The adjusted EBITDA margin also improved 20 basis points year over year.

BURL’s Financial Snapshot: Cash, Debt & EquityBurlington Stores ended the first quarter of fiscal 2026 with total liquidity of $1.69 billion, consisting of $747 million in unrestricted cash and $942 million of availability under its asset-based lending (“ABL”) facility.

Total outstanding debt at the quarter-end was $1.92 billion, including $1.72 billion under the Term Loan facility, $186 million in convertible notes and no borrowings under the ABL facility.

Burlington Stores repurchased $111 million of its outstanding 1.25% convertible notes in the fiscal first quarter. The transaction, valued at $173 million, was settled through a combination of $129 million in cash and the issuance of 150,831 shares of common stock.

The company also repurchased 257,906 shares of its common stock for approximately $81 million under its share repurchase program. At the end of the fiscal first quarter, $304 million remained available under the current share repurchase authorization.

BURL’s Store UpdateIn the first quarter of fiscal 2026, Burlington Stores opened 40 stores, relocated six and closed four stores, resulting in a net increase of 30 stores during the period. The company ended the quarter with 1,242 stores across 47 states, Washington DC and Puerto Rico.

BURL’s Q2 GuidanceFor the second quarter of fiscal 2026, Burlington Stores expects total sales to increase 10-12%, including comparable store sales growth of 1-3%. The company expects the adjusted EBIT margin to increase 30-60 basis points year over year, excluding $3 million of anticipated expenses associated with bankruptcy-acquired leases in the second quarter of fiscal 2026, whereas it registered $11 million in the prior-year period.

Management expects the margin improvement to be driven by higher merchandise margins, supported by markdown favorability, modestly faster inventory turns and a favorable shortage accrual rate versus last year. These benefits are expected to be partially offset by modest freight expense pressure related to higher fuel rates.

Burlington Stores also expects leverage in product sourcing costs as it continues to realize benefits from supply-chain productivity initiatives across its distribution center network. However, these savings will be partially offset by ongoing start-up costs related to the company's new distribution center in Savannah, GA, which became operational late in the fiscal first quarter. Management also expects SG&A expenses to provide modest leverage during the quarter.

The company anticipates an adjusted effective tax rate of 23% and adjusted earnings per share of $2.05-$2.20, whereas it reported an adjusted EPS of $1.72 in the second quarter of fiscal 2025. Management noted that sales trends in May were tracking at the high end of its comparable sales guidance range, although monthly comparisons are expected to become more challenging as the quarter progresses.

FY26 View for BURLFor fiscal 2026, Burlington Stores expects total sales to increase 9-11%, following a 9% increase in fiscal 2025. This compares with the prior guidance of 8-10%. The outlook assumes comparable store sales growth of 2-4%, on top of a 2% comparable sales increase in fiscal 2025. Previous estimation of comparable store sales growth was 1-3%.

The company expects to open 115 net new stores during the year, up from the prior mentioned 110 net new stores, with the majority of store openings anticipated to occur in the first half of the year.

Burlington Stores expects the adjusted EBIT margin to increase 10-30 basis points from that reported in fiscal 2025, excluding $10 million of anticipated expenses associated with bankruptcy-acquired leases in fiscal 2026 versus the $35 million registered in fiscal 2025.

Adjusted earnings per share are projected to be $11.45-$11.80, whereas it reported an adjusted EPS of $10.17 in fiscal 2025. The updated outlook implies year-over-year earnings growth of 13-16%. Previously, the adjusted EPS was projected between $10.95 and $11.45. The outlook assumes a share count of 64 million. Capital expenditure, net of landlord allowances, is expected to be $875 million.

Management noted that its outlook for the back half of fiscal 2026 remains unchanged. For the second half of the year, the company expects comparable store sales growth of 1-3%, total sales growth of 8-10%, the adjusted EBIT margin expansion of 10-30 basis points and earnings per share of $7.30-$7.50. Management also expects comparable sales upside in the fiscal third quarter and possibly the fourth quarter as Burlington Stores laps easier comparisons and prior-year tariff-related assortment gaps.

BURL Stock Past 6-Month Performance

Image Source: Zacks Investment Research

In the past six months, this Zacks Rank #3 (Hold) company has gained 24% compared with the industry’s 12.3% growth.

Key PicksWe have highlighted three better-ranked stocks, namely, Ross Stores Inc. (ROST - Free Report) , Victoria's Secret & Co. and Levi Strauss & Co. (LEVI - Free Report) .

Ross Stores operates as an off-price retailer of apparel and home accessories, primarily in the United States. It carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Ross Stores’ current fiscal-year earnings and sales indicates growth of 15.6% and 8.2%, respectively, from the year-ago actuals. ROST delivered a trailing four-quarter average earnings surprise of 10.2%.

Victoria's Secret is a specialty retailer of women's intimates, sleepwear, apparel, sport and swimwear, and prestige fragrances and body care. It currently has a Zacks Rank of 2. The company delivered a trailing four-quarter earnings surprise of 55.1%, on average.

The Zacks Consensus Estimate for VSCO’s current fiscal-year sales and earnings indicates growth of 6.2% and 16.3%, respectively, from the year-ago reported numbers.

Levi Strauss designs and markets jeans, casual wear and related accessories for men, women and children. It currently carries a Zacks Rank of 2.

The Zacks Consensus Estimate for Levi Strauss’ current fiscal-year earnings and sales suggests growth of 11.9% and 5.2%, respectively, from the year-ago actuals. LEVI delivered a trailing four-quarter average earnings surprise of 21.4%.

Burlington Stores Inc. NYSE: BURL delivered another better-than-expected quarter on May 28, marking its 14th consecutive quarter of double-digit earnings growth.

The company also raised its full-year outlook as off-price retailers continue to benefit from demand among budget-conscious consumers seeking bargains. Still, it wasn't enough to satisfy investors, as shares fell sharply following the report.

Get Burlington Stores alerts:

Burlington Earnings Beat Expectations Burlington Stores Today

BURL

Burlington Stores

$342.10 +15.09 (+4.61%)

As of 06/11/2026 03:59 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$218.52▼

$351.85P/E Ratio35.16

Price Target$353.56

For the quarter, the company reported adjusted earnings per share (EPS) of $2.01, an increase of 26% from year-ago earnings of $1.60 and well above Wall Street’s expectations of $1.77 per share. Revenue rose 14% year over year (YOY) to $2.86 billion, topping analyst estimates by more than $57 million.

Comparable-store (comp) sales increased 6% YOY, above the company’s guided range of 2% to 4%, while gross margin expanded 30 basis points to 44.1% of net sales.

On the earnings call, Chief Executive Michael O’Sullivan noted, “These results add to an already very impressive track record of consistently converting sales growth into strong margin expansion and earnings flow-through,” noted Chief Executive Michael O’Sullivan on the earnings call.

Burlington Raises Full-Year Guidance on Strong Off-Price DemandThe company also issued second-quarter guidance and raised its full-year sales and earnings outlook. For Q2, Burlington expects comp sales growth of 1% to 3%, with total sales increasing 10% to 12%. Operating margin is expected to expand 30 to 60 basis points YOY, while adjusted EPS is forecast to be between $2.05 and $2.20.

For the full year, Burlington now expects comp sales growth of 2% to 4%, up from prior guidance of 1% to 3%. Total sales are expected to rise 9% to 11%, up from the prior outlook of 8% to 10%, while adjusted EPS is projected between $11.45 and $11.80, above the previous forecast of $10.95 to $11.45. The company also noted it now expects its net new store openings to be 115, up from 110.

O’Sullivan also discussed how higher oil prices and the conflict in the Middle East have influenced the company’s outlook since the previous earnings call. Burlington remains optimistic about the second half of the year, though management is taking a more cautious view than it did in March because of higher gas prices and the potential impact on inflation.

Even so, O’Sullivan said a tougher consumer backdrop could work in Burlington’s favor if shoppers become more focused on value. "In fact, as a value retailer, it could turn into an opportunity," he said.

Shares Tumble Despite Strong Quarter and Better OutlookBurlington may have cleared Wall Street’s estimates, but not necessarily the market’s expectations. After the report, BURL stock initially fell nearly 8%, trading near $300, before recovering much of that decline in subsequent trading.

Burlington Stores, Inc. (BURL) Price Chart for Friday, June, 12, 2026

Ahead of the earnings release, the stock had been on a major multiyear run. After normalizing from pandemic-era highs, Burlington shares were trading around $110 in September 2022. Since then, the stock has surged roughly 175%, including a gain of more than 25% over the past year, leaving investors with a higher bar for another beat-and-raise quarter.

The post-earnings sell-off comes shortly after Burlington shares hit a 52-week high above $351 in April, potentially signaling some profit-taking following the stock’s multiyear run. It may also indicate that investors were looking for stronger comp sales growth and a more robust outlook for comparable-store sales.

During the earnings call, one analyst questioned whether Burlington’s focus on earnings may have caused it to miss opportunities to drive additional comp growth in Q1. In response, O’Sullivan said, “I do think that we may have an opportunity to loosen our belts a notch and get slightly more aggressive on sales.”

Burlington Sell-Off Contrasts With Off-Price PeersThe reaction to Burlington’s earnings was very different from some of its off-price peers, whose shares moved higher following their own better-than-expected earnings reports.

Shares of TJX Companies Inc. NYSE: TJX rose more than 5% after the company's recent earnings and revenue beats on May 20, while Ross Stores Inc. NASDAQ: ROST gained more than 8% two days later following its strong Q1 report.

In terms of valuation, the three stocks have similar price-to-earnings (P/E) ratios, with Burlington trading around 34x earnings, TJX at 30x, and Ross Stores at roughly 32x. The broader retail industry is trading at an average P/E ratio of 25x.

Burlington Stores Stock Forecast Today12-Month Stock Price Forecast:
$353.56
3.35% Upside

Moderate Buy
Based on 20 Analyst Ratings

Current Price$342.10High Forecast$411.00Average Forecast$353.56Low Forecast$310.00Burlington Stores Stock Forecast Details

Despite Burlington’s post-earnings decline, Wall Street analysts remain largely bullish on the stock.

Ahead of the report, the average 12-month price target stood around $357, implying more than 18% upside from current levels.

The stock currently carries a Moderate Buy consensus rating, based on 16 Buy ratings and five Hold ratings. The $351 analyst consensus price target implies about an 8% potential upside.

While Burlington’s latest quarter highlighted the continued strength of the off-price sector, the market reaction suggests investors may have been hoping for more signs of strength in comparable-store sales.

Still, with consumers remaining focused on value amid economic uncertainty, Burlington could be well-positioned if bargain hunting continues to drive retail spending.

Should You Invest $1,000 in Burlington Stores Right Now?Before you consider Burlington Stores, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burlington Stores wasn't on the list.

While Burlington Stores currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

BURLINGTON, Ontario, June 03, 2026 (GLOBE NEWSWIRE) -- Located in the heart of Burlington, Ontario, Medical Grade Physiotherapy & Wellness is proud to announce the that it is officially accepting new clients in its modern multidisciplinary rehabilitation clinic dedicated to delivering personalized physiotherapy, chiropractic care, massage therapy, sports rehabilitation, injury recovery, and wellness services for the Burlington community and surrounding cities.

Patients can learn more or book appointments directly through Medical Grade Physiotherapy & Wellness.

Designed with a patient-first philosophy, Medical Grade Physiotherapy & Wellness was created to offer a higher standard of rehabilitation care — focusing on individualized treatment, evidence-based therapy, and hands-on one-on-one sessions that prioritize long-term recovery over rushed appointments.

The clinic offers comprehensive services including physiotherapy, chiropractic care, registered massage therapy, sports physiotherapy, motor vehicle accident rehabilitation (MVA), workplace injury rehabilitation (WSIB), chronic pain management, post-surgical rehabilitation, mobility restoration, and preventative wellness care.

A Mission Focused on Exceptional One-on-One Care

At the core of Medical Grade Physiotherapy & Wellness is a simple but powerful mission:

“To provide exceptional one-on-one care that helps every patient move better, recover faster, and live healthier with confidence.”

Unlike many high-volume rehabilitation clinics, each practitioner at Medical Grade Physiotherapy & Wellness works with patients in private treatment rooms to ensure focused attention, comfort, confidentiality, and personalized rehabilitation planning. The clinic’s evidence-based approach emphasizes identifying the root cause of pain and dysfunction — not simply masking symptoms.

“Our goal is to create an environment where patients feel heard, supported, and genuinely cared for,” said the team at Medical Grade Physiotherapy & Wellness. “Every treatment plan is tailored to the individual because no two injuries, bodies, or recovery journeys are the same.”

Supporting Burlington & Surrounding Communities

Conveniently located on Guelph Line in Burlington, the clinic proudly serves patients throughout Downtown Burlington, Aldershot, Alton Village, Tyandaga, Shoreacres, Pinedale, Longmoor, and Elizabeth Gardens, while also welcoming patients from Oakville, Hamilton, Milton, Waterdown, Ancaster, Dundas, Stoney Creek, Grimsby, Flamborough, and Mississauga.

As Burlington continues to grow as one of Southern Ontario’s most active and health-conscious communities, the clinic aims to become a trusted destination for rehabilitation, injury prevention, mobility improvement, and overall wellness.

A Modern, Evidence-Based Approach to Rehabilitation

Medical Grade Physiotherapy & Wellness combines clinical expertise with modern rehabilitation strategies to help patients achieve lasting results. Treatment plans may include:

Hands-on manual therapyCorrective exercise programmingMobility and flexibility trainingPostural correctionSports injury rehabilitationStrength and conditioning supportChronic pain managementWorkplace ergonomic educationAdvanced rehabilitation modalitiesMassage therapy and chiropractic integration The clinic treats a wide range of conditions including back pain, neck pain, sports injuries, repetitive strain injuries, post-operative recovery, mobility limitations, headaches, posture-related dysfunctions, and joint pain.

Patient Testimonials Reflect a Commitment to Care

Early patient experiences have already highlighted the clinic’s dedication to high-quality care and personalized treatment.

One Burlington patient shared:

“From my first appointment, I felt genuinely listened to. The team took the time to understand my pain instead of rushing through treatment. I noticed improvements in my mobility and pain levels within weeks.”

Another patient recovering from a sports-related injury stated:

“The one-on-one attention made a huge difference. Every session felt customized to my recovery goals. The clinic atmosphere is modern, welcoming, and professional.”

A patient dealing with chronic neck and back pain added:

“I’ve been to several clinics over the years, but this experience felt completely different. The treatment approach was thorough, educational, and focused on long-term recovery rather than temporary relief.”

A Growing Demand for Personalized Physiotherapy in Burlington

As more patients seek individualized healthcare experiences, demand for evidence-based physiotherapy and rehabilitation services continues to rise across Burlington and the Halton Region. Community discussions frequently highlight the importance of conservative therapy options such as physiotherapy, chiropractic care, exercise rehabilitation, and manual therapy for addressing chronic pain and mobility issues.

Medical Grade Physiotherapy & Wellness aims to meet this growing need by combining compassionate care with modern rehabilitation techniques in a patient-centered environment.

What you can expect

Comprehensive, Patient-Focused Care
Every treatment plan begins with a detailed assessment designed to identify the root cause of pain, mobility limitations, and movement dysfunction. Using evidence-based techniques and personalized goal setting, our team creates customized rehabilitation programs focused on long-term recovery, strength, and performance.

Multidisciplinary Therapy Services
Our Burlington clinic offers integrated physiotherapy, chiropractic care, registered massage therapy, sports rehabilitation, pelvic health therapy, vestibular rehabilitation, custom orthotics & braces, and chronic pain management—all under one roof. This collaborative approach ensures seamless care from injury recovery to full-body wellness.

Modern Clinic With Advanced Rehabilitation Technology
Designed for comfort and results, our clinic features private treatment rooms, advanced therapeutic equipment, and functional exercise spaces to support mobility, stability, posture correction, and injury prevention. We combine hands-on therapy with active rehabilitation to help patients recover faster and move better.

Convenient Scheduling & Direct Insurance Billing
We offer flexible extended hours, virtual appointments, direct billing to most major insurance providers, and support for WSIB and motor vehicle accident claims. Our goal is to make high-quality rehabilitation and pain relief care accessible, efficient, and stress-free for every patient.

Booking link: https://medicalgradephysio.janeapp.com/

About Medical Grade Physiotherapy & Wellness

Medical Grade Physiotherapy & Wellness is a multidisciplinary rehabilitation and wellness clinic located in Burlington, Ontario. The clinic specializes in physiotherapy, chiropractic care, massage therapy, sports injury rehabilitation, chronic pain management, MVA rehabilitation, workplace injury treatment, and personalized wellness care.

With a strong emphasis on one-on-one treatment, evidence-based rehabilitation, and patient education, the clinic is committed to helping individuals restore movement, reduce pain, improve function, and achieve long-term health outcomes.

For appointments, services, or additional information, visit Medical Grade Physiotherapy & Wellness Official Profile or call 289-337-2288.
700 Guelph Line Unit #4 Burlington, ON L7R 3M8 Canada
Medical Grade Physiotherapy & Wellness

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1187d812-4a9f-4e51-b6a4-526604c66b37

Medical Grade Physiotherapy & Wellness Storefront Medical Grade Physiotherapy & Wellness in Burlington Physiotherapy • Sports Injury Rehabilitation • ...

Earnings season from Q2 is winding down, and many components of the S&P 500 have reported spectacular results, especially those in the AI supply chain.

When companies like NVIDIA and Alphabet report earnings, the market tends to grab its popcorn and wait for fireworks. But not every big Q2 earnings winner is in the AI ecosystem.

In fact, many of the market’s biggest beats came from under-the-radar companies that are quietly executing their strategies.

Those are the companies we’ll be focusing on today.

Here are five that reported excellent earnings last week that may not be on your watchlist.

Victoria’s Secret and Co.Victoria’s Secret (NYSE:VSXY) recently switched tickers from VSCO to VSXY, and with the new ticker came a renewed rally as its fiscal Q1 2026 earnings results smashed expectations.

For the quarter ending May 2nd, Victoria’s Secret reported revenue of $1.56 billion, up 15% year-over-year (YoY) and above the midlevel consensus of $1.52 billion. Comp sales were up 12% YoY, with broad-based growth across the Victoria’s Secret, Beauty, and PINK brands.

However, it was the bottom line that drove the stock up nearly 50% following the release. The company reported EPS of $0.60, a 500% YoY increase and double the expected $0.30. Operating income also rose to $80 million thanks to margin expansion, which is an impressive feat considering the company’s vulnerability to tariffs.

Victoria’s Secret raised both Q2 and full-year guidance, and now expects revenue between $7.03 billion and $7.18 billion in fiscal 2026. The stock response was explosive, but a few technical indicators had been flashing before the blowout earnings news. A Golden Cross began the uptrend last fall, but the stock had spent most of 2026 in consolidation.

However, both the Relative Strength Index (RSI) and the Moving Average Convergence Divergence (MACD) indicators triggered bullish signals in late May, hinting that an earnings beat was in the works. And despite the sizable gain, VSXY shares still trade at just 22 times forward earnings and 0.95 times sales.

Okta Inc.Okta’s fiscal Q1 2027 report was a double beat with a guidance raise, and investors rewarded it by sending the stock up 30% after hours. Revenue grew 12% YoY to $765 million, its fifth straight record-setting quarter and well above the $751 million consensus. The $0.91 EPS figure also beat the expected $0.85, and the company raised fiscal 2027 revenue guidance range to $3.19 billion to $3.21 billion. 

Once again, technical signals were the map to the buried treasure. Okta reported earnings on May 28th, but the RSI nudged into bullish territory before April had ended. The MACD also confirmed the trend reversal with a bullish crossover, and the price quickly broke resistance at the 50-day moving average. Shares have pulled back 10% this week as investors took profits, but this could also be an opportunity to open new positions.

Burlington also raised its sales growth guidance range to 9% to 11%, and growth is a must for a retailer trading at 33 times earnings and 1.7 times sales. Trading in BURL shares had been volatile, but the earnings report has revived the uptrend, pushing the share price back above the 50-day moving average. The RSI is also back in bullish territory, giving more strength to the upward momentum.

Science Applications International Corp.Management reaffirmed full-year revenue guidance, which limits the stock’s upside a bit, as opposed to a beat and raise. But strong margins appear ready to carry the day, and the stock is in full breakout mode. The price ripped through the 50-day and 200-day moving averages shortly before the earnings boost, and the MACD shows strong upward momentum.

Elastic N.V.ESTC shares had been in a long decline, losing more than 20% of their value over the last 12 months. But recently, a breakout has been bubbling under the surface. The RSI and MACD both flipped bullish in early April, and the share price overtook the 50-day moving average a few weeks later. The earnings report provided another catalyst, and now shares are challenging the 200-day moving average for the first time since March 2025.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

After reaching an important support level, Burlington Stores (BURL - Free Report) could be a good stock pick from a technical perspective. BURL surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first marker of an up or down trend.

BURL could be on the verge of another rally after moving 12.3% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.

The bullish case solidifies once investors consider BURL's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 3 higher, while the consensus estimate has increased too.

Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on BURL for more gains in the near future.

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-running managers for the offering.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at [email protected]; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at [email protected] and [email protected]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ expectations regarding the completion, timing and size of the proposed offering. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, risks and uncertainties related to whether or not Cytokinetics will be able to raise capital through the sale of its securities, the final terms of the proposed offering, market and other conditions, and the satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Cytokinetics will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the proposed public offering, Cytokinetics and its business can be found under the heading “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on February 26, 2026, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed on May 5, 2026, and other filings with the SEC, and in the preliminary prospectus supplement related to the proposed public offering to be filed with the SEC on or about the date hereof. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call Prepared Remarks Transcript

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $71.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $700 million. The offering is expected to close on May 8, 2026, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,478,873 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-running managers for the offering. Mizuho is acting as lead co-manager for the offering and Citizens Capital Markets, Needham & Company, B. Riley Securities and H.C. Wainwright & Co. are acting as co-managers for the offering.

The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed, and a final prospectus supplement and accompanying prospectus relating to the offering will be filed, with the SEC and can be accessed for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at [email protected]; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at [email protected] and [email protected]; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ expectations regarding the completion of the offering. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, risks and uncertainties related to market and other conditions, and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Cytokinetics will be able to complete the public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the public offering, Cytokinetics and its business can be found under the heading “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on February 26, 2026, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed on May 5, 2026, and other filings with the SEC, and in the preliminary prospectus supplement related to the public offering, filed with the SEC on May 5, 2026. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety  SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten.

Collectively, the new evidence expands understanding of the effectiveness of cardiac myosin inhibition with aficamten compared directly to metoprolol, a beta blocker, as well as specific safety and durability characteristics of MYQORZO across patient demographics, clinical, and economic subgroups.

“The breadth of research being presented at ESC Heart Failure 2026 reflects our commitment to deepening the scientific understanding of oHCM and heart failure,” said Stephen Heitner, M.D., Senior Vice President, Clinical Research and Development, Cytokinetics. “These new insights underscore the strength and consistency of the clinical profile of MYQORZO, adding to the growing body of real-world evidence informing physician treatment decisions.”

New Analyses Show MYQORZO Outperforms Metoprolol Across Sex and Doses

A dose-dependent analysis from MAPLE-HCM compared aficamten to the beta-blocker metoprolol in patients with symptomatic oHCM. Key findings showed significant improvements in exercise capacity, outflow gradients, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) across all treatment doses. Conversely, metoprolol failed to show improvement in these outcomes regardless of the dose administered (Figure 1).

Figure 1

A secondary analysis of sex differences in MAPLE-HCM showed consistent benefits of MYQORZO in women. Despite women entering the trial (42%) with more severe baseline characteristics, MYQORZO delivered nearly identical improvements in peak oxygen consumption (pVO2) for both sexes (+2.2 mL/kg/min). Both groups also saw significant gains in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and reductions in cardiac biomarkers and NT-proBNP.

Long-term Data Reinforce Safety and Efficacy Profile of MYQORZO

A prospective analysis of 122 patients who had interpretable ambulatory electrocardiogram (ECG) data at screening in the FOREST-HCM showed that long-term treatment with MYQORZO—up to 96 weeks—did not increase the incidence of arrhythmias in patients, including those who underwent withdrawal of beta-blocker therapy.

Among 122 patients, the incidence of non-sustained ventricular tachycardia (NSVT) on ambulatory ECG remained stable through 96 weeks compared with baseline, with no increase in atrial fibrillation (AF) episodes and no newly identified subclinical AF. There was also no increase in arrhythmia frequency among a subgroup of 16 patients who discontinued beta-blocker therapy during aficamten treatment. These results represent the first prospective analysis of ambulatory ECG monitoring in patients treated with a cardiac myosin inhibitor and are consistent with the low incidence of clinically detected arrhythmias previously reported for patients with oHCM treated with aficamten.

Additionally, an open-label extension study of aficamten in Chinese patients with symptomatic oHCM showed that aficamten was well tolerated using the same dosing strategy of individualized titration as was used globally. Through 48 weeks of treatment with aficamten, patients experienced no serious or severe treatment-emergent adverse events, no occurrences of LVEF <50% and no treatment discontinuations. Significant and durable improvements from baseline were observed in resting and Valsalva left ventricular outflow tract (LVOT) gradients (−40.3 mmHg and −45.6 mmHg, respectively; both p<0.001), New York Heart Association (NYHA) Functional Class ≥1 (15% p = 0.024), KCCQ-CSS (+8.3 points; p<0.001) and NT-proBNP (−59.2%; p<0.001).

New Evidence Indicates Positive Effects of MYQORZO on Left Atrium Remodeling and Atrial Mechanics

Expanded insights from SEQUOIA-HCM provide the first-ever analysis of the effect of aficamten on left atrial (LA) mechanics in oHCM. This analysis was performed to determine whether MYQORZO improved LA function in addition to previously demonstrated improvement in exercise capacity by relieving left ventricular outflow tract (LVOT). The new data showed that across the key clinical subgroups, MYQORZO, compared with placebo, significantly improved LA mechanics, which correlated with improvement in functional capacity in oHCM.

Among 269 patients, LA function was abnormal at baseline, with 94% of participants having reduced LA reservoir and conduit strain. Compared with placebo, aficamten significantly improved LA reservoir strain (treatment effect +2.9%; p=0.004) and absolute LA conduit strain (+2.2%; p=0.001) and reduced LA volume index (−3.5 mL/m2; p<0.001). These findings extend prior evidence that aficamten favorably remodels left atrial structure and suggest a beneficial effect on atrial mechanics.

Real-World Evidence Highlights Unmet Need and the Significant Burden of HCM

Multiple presentations provide new multinational real-world evidence and health economics and outcomes data underscoring the burden of HCM across disease subtypes and need for effective therapies that address the underlying disease mechanisms of HCM in adult and pediatric patients across the spectrum of symptomatic disease.

Work & Activity Impairment:
A survey of 273 patients in Italy, Spain and the United States revealed that patients with oHCM reported, on average, 26.6% activity impairment due to the disease. Full-time and part-time employed patients with HCM reported that 15.35% of their time at work was impaired due to HCM in the past 7 days and, on average, they missed 1.63% of work time. Activity impairment was significantly higher among those with oHCM compared with non-obstructive HCM (nHCM) (30.2% vs 19.2%; p=0.0003).

A separate analysis of 701 U.S. patients with HCM from the Adelphi Real World Disease Specific Programme™, showed that patients classified as NYHA II–IV Functional Class reported higher symptom burden, greater cardiovascular comorbidity, greater healthcare resource utilization (including emergency room (ER) visits, day visits and caregiver hours) and lower quality of life (EQ-5D-5L and EQ-VAS) compared with patients in NYHA Class I. Notably, patients in NYHA Class I continued to experience clinical symptoms and require medical care, underscoring the need for therapies that address the underlying mechanisms of HCM across the spectrum of symptomatic disease.

Limitations of Current Therapy:
An analysis of 723 patients with nHCM showed that despite 70% being on guideline-directed medical therapy such as beta-blockers, they continued to experience substantial clinical and economic burdens.

Clinical Burden of Pediatric Hypertrophic Cardiomyopathy:
A retrospective cohort study characterized the real-world epidemiology of pediatric HCM in the United States using administrative claims data from 6,093 children and adolescents diagnosed between 2016 and 2024. Approximately one in four children with HCM had obstructive disease (23.6%), and roughly one in four were symptomatic at presentation, underscoring the needs of the pediatric oHCM population that may be targeted by emerging disease-modifying therapies, including aficamten, which is currently under investigation in CEDAR-HCM, a Phase 3 trial in pediatric patients with oHCM.

A separate study analyzed the phenotypic distribution and clinical burden of pediatric HCM based on a longitudinal U.S. claims database, showing that pediatric patients with HCM experience substantial clinical burden. Obstructive HCM was associated with a higher cumulative risk of cardiovascular events compared with nHCM. These findings demonstrate clinically relevant heterogeneity in pediatric HCM and may inform risk mitigation strategies.

About MYQORZO® (aficamten)

MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China and European Union for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.1

Aficamten was studied in ACACIA-HCM, a completed Phase 3 clinical trial of aficamten in patients with nHCM, and is also under clinical investigation in CEDAR-HCM in a pediatric population with oHCM. Aficamten has not been deemed safe or effective for use in this patient population. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction.  Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program.  CONTRAINDICATIONS

MYQORZO is contraindicated with concomitant use of rifampin.

WARNINGS AND PRECAUTIONS

Heart Failure

MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.

Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.

Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.

Initiation of MYQORZO in patients with LVEF <55% is not recommended.

MYQORZO REMS Program

MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.

Notable requirements of the MYQORZO REMS Program include:

Prescribers must be certified by enrolling in the MYQORZO REMS ProgramPatients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirementsPharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZOWholesalers and distributors must only distribute to certified pharmacies Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.

Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness

MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.

Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.

ADVERSE REACTIONS

Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo in the pivotal trial.

INDICATIONS AND USAGE

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Please see full prescribing information, including BOXED WARING, for MYQORZO.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.

HCM is the most common monogenic inherited cardiovascular disorder, with well over 300,000 patients diagnosed in the U.S.2 However, there are an estimated 400,000-800,000 additional patients who remain undiagnosed.3,4,5 Recent analysis of a large claims database indicates that approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM).2

People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.6 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.7 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics’ research and development activities; clinical trial initiation, design, enrollment, conduct, progress, continuation, completion, timing and results; regulatory submissions, review processes, approval timing and outcomes, including with respect to supplemental applications and approvals in jurisdictions outside the United States; the scope, expansion, modification, durability or continuation of labeling and promotional claims; commercial readiness, launch timing, market access and reimbursement; anticipated patient, prescriber and payer adoption; expectations regarding market opportunity, growth and market share; pipeline development and expansion into additional indications or geographies; access to and use of capital; and Cytokinetics’ business strategy, objectives and future plans. Such statements are based on management's current expectations and assumptions; however, actual results may differ materially due to various risks and uncertainties, including, but not limited to, uncertainties inherent in drug development and commercialization; the timing, conduct and outcomes of clinical trials; regulatory review and approval processes in the United States and other jurisdictions; differences in regulatory requirements, labeling, market access or promotional restrictions across jurisdictions; the ability to obtain, expand, maintain or continue desired labeling, promotional claims or commercial positioning for approved products; potential legal, intellectual property or regulatory constraints affecting commercialization and marketing claims; patient and prescriber acceptance of MYQORZO as compared to alternative therapies; the availability and terms of reimbursement from commercial and government payers; manufacturing, supply and distribution risks; competition; and the availability of sufficient capital to execute Cytokinetics’ business plans. These forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission (the “SEC”).

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

References

Hartman JJ, Hwee DT, Roebrt-Paganin J, et al. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024;3(8) :1003-1016. doi:10.1038/s44161-024-00505-0Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 doi:10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575Symphony Health 2016-2021 Patient Claims Data DoF;Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5179347f-327c-44f4-9e9c-4e74b9ade881 

Third Annual Muscle Biology-Focused Research Symposium 
Highlighting Recent Innovations in the Field

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 29, 2026 from 8:00 AM to 5:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA.

Registration for the symposium is now open and available at no cost to attendees; however, capacity is limited. Interested parties must register online by May 22, 2026, at https://climbsymposium.com/.

“CLIMB has become an important forum for advancing dialogue and discovery in muscle biology,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As the science continues to evolve, we are proud to convene researchers and innovators whose work is deepening our understanding of the underlying mechanisms of muscle function and uncovering new frontiers in the field.”

CLIMB is an annual one-day in-person research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the biological understanding and emerging treatment of muscle-related diseases and disorders. CLIMB will feature distinguished expert speakers alongside poster presentations of novel research in the field of muscle biology. Presentations will focus on innovations in cardiac biology, skeletal muscle biology and emerging treatment modalities in muscle biology.

CLIMB 2026 will feature the following presentations:

Keynote:

Myosin: An Exquisite Nanomachine and the Power of Basic Research in Drug Discovery
James A. Spudich, PhD
Co-Founder, Cytokinetics
Stanford University, School of Medicine, Department of Biochemistry Session 1: Cardiac Biology

Chromatin Control of Cardiac Inflammation, Disease and Repair
Michael Alexanian, PhD, Gladstone Institute, University of California, San Francisco Energy Metabolism in Cardiomyopathy and Heart Failure
Rong Tian, MD, PhD, Mitochondria & Metabolism Center, University of Washington Immune-Mediated Cardiac Injury: From Checkpoints to Gene Therapies
Javid Moslehi, MD, University of California, San Francisco Session 2: Skeletal Muscle Biology

Harnessing the Regenerative Potential of Human Pluripotent Stem Cell Derived Skeletal Muscle Stem Cells
April Pyle, PhD, University of California, Los Angeles Modeling and Treating Disease by In Vivo Gene Editing with AAV-CRISPR
Amy J. Wagers, PhD, Harvard University and Joslin Diabetes Center Genetic Modifiers of Myopathies
Elizabeth McNally, MD, PhD, Northwestern University Feinberg School of Medicine Session 3: Emerging Modalities to Treat Human Muscle Disease

Emerging Genetic Medicines for Cardiomyopathies
Laura Lombardi, PhD, Tenaya Therapeutics Unlocking the Broad Potential of RNA Medicines to Transform Human Health
Erik Ingelsson, MD, PhD, Wave Life Sciences Weight Loss and Muscle Preservation
Siddique Abbasi, MD, MSc, Amgen About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a trademark of Cytokinetics in the U.S., and a registered trademark in the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance.

Stockholders of record at the close of business on March 31, 2026, are entitled to vote at Cytokinetics’ Annual Meeting of Stockholders or to attend in person and submit questions to management. Stockholders wishing to vote must attend the meeting in person or submit a valid proxy card by mail, telephone or internet by 11:59 PM Eastern Time on May 26, 2026, in accordance with instructions contained in our Proxy Statement for the 2026 Annual Meeting of Stockholders.

Interested parties may access the live webcast of the Annual Meeting of Stockholders and the subsequent presentation at the following link: Cytokinetics Annual Meeting of Stockholders. An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer 

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
+1 (415) 290-7757

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

European Launch Follows Strong U.S. Start

SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.

Marking the first of several planned European launches, the availability of MYQORZO in Germany follows the European Commission approval in February 2026. The approval was based on positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM, demonstrating robust efficacy, safety, and clinically meaningful benefits across symptoms, exercise capacity, hemodynamics, and biomarker endpoints.1 These clinical results were published in the New England Journal of Medicine.

“Bringing MYQORZO to Europe marks an exciting new chapter for Cytokinetics as we extend our reach to more patients with symptomatic oHCM,” said Joseph Dagher, Senior Vice President and Head of Europe, Cytokinetics. “This milestone further strengthens our leadership in muscle biology and reinforces Cytokinetics’ commitment to the global HCM community.”

MYQORZO was previously approved in December 2025 by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical Products Administration (NMPA) for the treatment of adults with NYHA class II-III oHCM, to improve exercise capacity and symptoms.

“The latest advancement in myosin inhibition brings a new treatment option into our clinical practice in Europe and Germany to help patients with symptomatic oHCM,” said Prof. Benjamin Meder, FESC, Chair of Precision Digital Health, Head of the Institute for Cardiomyopathies Heidelberg and Deputy Medical Director, Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg.

The results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing (CPET) by 1.76 mL/kg/min compared to baseline in patients treated with MYQORZO versus 0.0 mL/kg/min in patients treated with placebo (least square mean (LSM) difference [95% CI] of 1.74 mL/kg/min [1.04 - 2.44]; p=0.000002).1 The treatment effect of MYQORZO was consistent across all prespecified subgroups, including age, sex, patient baseline characteristics, and in patients receiving or not receiving background beta-blocker therapy.

Statistically significant (p<0.0001) and clinically meaningful improvements were also observed in all 10 prespecified secondary endpoints, including Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at weeks 12 and 24, the proportion of patients with ≥1 class improvement in New York Heart Association (NYHA) functional class at weeks 12 and 24, change in provoked left ventricular outflow tract gradient (LVOT-G) and proportion <30 mmHg at weeks 12 and 24, as well as exercise workload and guideline-eligibility for septal reduction therapy.

“Obstructive HCM can have life-altering effects on all aspects of patients’ lives and having more treatments options allows for more personalized choices based on their symptoms and lifestyle,” said Emil Tsenov, Founding and Managing Director, HCM Patient Foundation. “The availability of MYQORZO in Germany brings hope for patients around the European Union and reflects meaningful progress for the HCM community.”

About MYQORZO® (aficamten)

MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China and European Union for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.1

Aficamten was studied in ACACIA-HCM, a completed Phase 3 clinical trial of aficamten in patients with nHCM. Aficamten is also under clinical investigation in CEDAR-HCM in a pediatric population with oHCM. Safety and efficacy of aficamten have not been established in a pediatric patient population. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.

Please see full Summary of Product Characteristics approved in the European Union.

Please see full Prescribing Information approved in the U.S., including Boxed WARNING and Medication Guide.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.

HCM is the most common monogenic inherited cardiovascular disorder, affecting approximately 1 out of 350 individuals worldwide.2

Approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM).3

People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.4 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.5 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics’ research and development activities; clinical trial initiation, design, enrollment, conduct, progress, continuation, completion, timing and results; regulatory submissions, review processes, approval timing and outcomes, including with respect to supplemental applications and approvals in jurisdictions outside the United States; the scope, expansion, modification, durability or continuation of labeling and promotional claims; commercial readiness, launch timing, market access and reimbursement; anticipated patient, prescriber and payer adoption; expectations regarding market opportunity, growth and market share; pipeline development and expansion into additional indications or geographies; access to and use of capital; and Cytokinetics’ business strategy, objectives and future plans. Such statements are based on management's current expectations and assumptions; however, actual results may differ materially due to various risks and uncertainties, including, but not limited to, uncertainties inherent in drug development and commercialization; the timing, conduct and outcomes of clinical trials; regulatory review and approval processes in the United States and other jurisdictions; differences in regulatory requirements, labeling, market access or promotional restrictions across jurisdictions; the ability to obtain, expand, maintain or continue desired labeling, promotional claims or commercial positioning for approved products; potential legal, intellectual property or regulatory constraints affecting commercialization and marketing claims; patient and prescriber acceptance of MYQORZO as compared to alternative therapies; the availability and terms of reimbursement from commercial and government payers; manufacturing, supply and distribution risks; competition; and the availability of sufficient capital to execute Cytokinetics’ business plans. These forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission (the “SEC”).

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.

References
1. Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424
2. Tsenov et al. Healthcare access, symptom burden, and psychological impact in hypertrophic cardiomyopathy: a multinational patient-driven survey. Int J Cardiol Cardiovasc Risk Prev2025 Aug 4;27:200485. doi: 10.1016/j.ijcrp.2025.200485
3. Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552
4. Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
5. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21

Contact:
Diane Weiser
Senior Vice President, Corporate Affairs
+1 (415) 290-7757

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values

Deadline for Applications is August 3, 2026

SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support equitable healthcare initiatives for cardiovascular disease, science education and certain essential services for local and at-risk communities.

“At Cytokinetics, our commitment to the communities around us is as fundamental to our mission as the science we pursue,” said Diane Weiser, Cytokinetics’ Senior Vice President, Corporate Affairs. “Through this program, we are proud to support the non-profit organizations on the front lines of building a future where everyone has a fair chance at health and opportunity.”

The Cytokinetics Corporate Giving Program consists of individual charitable donations up to $20,000 for qualified 501(c)(3) organizations in the United States that are neither engaged, nor directly involved in the practice of healthcare. Specifically, the program will provide funding to organizations with initiatives focused on science education and certain essential services for local and at-risk communities in the San Francisco Bay Area and Greater Philadelphia Region. Additionally, it will support eligible organizations dedicated to health equity initiatives in cardiovascular disease across the United States. Applications may now be submitted online at https://www.cybergrants.com/Cytokinetics/corporate_giving_eligibility.

The deadline to apply for the Cytokinetics Corporate Giving Program is August 3, 2026. For more information on the program, including eligibility details, guidelines and specifics, visit https://cytokinetics.com/responsibility/grants-and-giving-programs/corporate-giving-program/.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

Asana, Inc. (NYSE: ASAN - Get Free Report)'s stock price reached a new 52-week low during trading on Friday. The stock traded as low as $6.31 and last traded at $6.3850, with a volume of 544955 shares traded. The stock had previously closed at $6.68. Analysts Set New Price Targets Several equities analysts recently issued

Avis Budget Group Today

CAR

Avis Budget Group

$189.61 +2.78 (+1.49%)

As of 06/11/2026 04:00 PM Eastern

52-Week Range$85.96▼

$847.70Price Target$129.63

Investors felt like it was 2021 all over again when shares of Avis Budget Group NASDAQ: CAR soared from $100 to $850 in just over three weeks.

No announcement or breakthrough caused the surge; just a classic short squeeze story involving an artificially-limited float and unbridled risk-seeking behavior.

Get Groupon alerts:

The squeeze was orchestrated by a pair of hedge funds that effectively gained control of the entire float. Through stock and swaps, Pentwater Capital and SRS Investment Management controlled more than 80% of the float in a stock already seeing 13% short interest.

As a result, basically no shares were available for shorts to cover, and the feedback loop sent the stock up more than 500%. Like most short squeezes, the trade quickly unwound, and CAR shares are back in the low $200's. But this episode was a great refresher on short-squeeze mechanics and also could set the stage for the next batch of squeezes.

3 Stocks With High Short Interest That Could Squeeze NextA true short squeeze requires three elements: a high level of short interest, a lengthy days to cover period, and a catalyst that can ignite a rally.

High short interest, with more than 5 days to cover, may create a difficult environment for short sellers to locate shares to close their positions. And when shorts are scrambling to cover while buyers pour in, that’s when the feedback loop of the short squeeze really sets in. Here are three stocks that match these criteria.

Groupon: Clean Short Squeeze Setup With Upcoming Earnings CatalystGroupon Today

$16.87 +0.78 (+4.85%)

As of 06/11/2026 04:00 PM Eastern

52-Week Range$9.17▼

$43.08Price Target$28.67

Online discounting marketplace Groupon Inc. NASDAQ: GRPN is always a popular short-squeeze candidate thanks to its earnings volatility and its general inability to turn revenue into profit.

And the shorts have mostly been rewarded over the years as GRPN shares have lost more than 65% of their value over the last five years.

But heavily shorted stocks often provide brief windows of opportunity, and Groupon has the classic short-squeeze setup that traders often seek.

First, GRPN has more than 50% of its float sold short, up more than 5% from the previous month. The stock entered the year with about 40% of the float sold short, so this is an acceleration from earlier levels. And crucially, shorts would need roughly 11.3 days to cover under average trading volume, which opens a lengthy window for a short squeeze to materialize.

In addition to the classic high short interest plus high days to cover combo, Groupon has a catalyst on the horizon with its Q1 2026 earnings release on May 6. An upside surprise could put more pressure on shorts, as the stock has already popped more than 30% in the last month.

Ignore the recent pullback; the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) indicator both show swelling buying momentum ahead of the earnings catalyst.

Asana: Founder Control Shrinks the Tradable SupplyAsana Today

$7.48 -0.11 (-1.39%)

As of 06/11/2026 03:59 PM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$5.38▼

$15.71Price Target$9.27

Asana Inc. NYSE: ASAN is the work management software platform founded by Dustin Moskovitz, one of the original designers of Facebook and a tech sector staple.

The company has struggled to achieve profitability over its nearly two decades of operations, but recently posted back-to-back positive EPS figures in fiscal Q3 and Q4 2026.

It also posted record revenue of $205.57 million in Q4 2026, which represented more than 9% year-over-year (YOY) growth. Sentiment may be turning in Asana; the stock received a rare upgrade from the Royal Bank of Canada in early April, and the share price has been trending up for the last few weeks.

Nearly 35% of the float is sold short in ASAN, with about 4.2 days to cover. That combo is already an intriguing short-squeeze setup, but Moskovitz’s controlling stake is so large that it artificially reduces the number of shares available for trading. He’s also been a relentless buyer during downturns, creating a dynamic similar to what unfolded at Avis.

Short interest is at its highest level since 2022, but indicators like the RSI and MACD suggest selling pressure is subsiding, and a steady influx of buyers could be the catalyst to ignite the squeeze.

Beyond Meat: Product News and Earnings Keep Volatility ElevatedBeyond Meat Today

$0.70 +0.02 (+3.15%)

As of 06/11/2026 04:00 PM Eastern

52-Week Range$0.50▼

$7.69Price Target$0.83

Few stocks have incinerated capital like Beyond Meat Inc. NASDAQ: BYND, which is down more than 99% since its 2019 IPO.

But that hasn’t stopped management from trying new things, and a few catalysts have the stock actually up more than 30% this month.

First, the company announced a partnership with Big Geyser for a protein-enhanced sports drink called Beyond Immerse. It also launched a new line of breakfast sausages and spicy chicken pieces, the latter to be sold exclusively at Kroger NYSE: KR.

With more than 31% of the float sold short and about 4.0 days to cover, the stock has the technical underpinnings for a short squeeze. A bullish MACD crossover triggered a trend reversal in early April, and now the RSI is back in bullish territory for the first time since early March. The company reports earnings on May 6, so another potential catalyst is waiting in the wings.

Should You Invest $1,000 in Groupon Right Now?Before you consider Groupon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Groupon wasn't on the list.

While Groupon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

SAN FRANCISCO--(BUSINESS WIRE)--Asana, Inc. (NYSE: ASAN)(LTSE: ASAN), the operating system for human-agent teams, today announced it has completed the acquisition of StackAI. StackAI is a no-code AI workflow platform that enables companies to design, test, deploy and govern custom AI agents and intelligent automation of business-critical workflows. The platform connects workflows, data, and actions across enterprise systems such as ERP, CRM and ITSM, to automate operational processes like custo.

Asana has acquired the workflow automation company StackAI for $75 million, part of a larger effort to position itself as an AI-native workplace platform. StackAI’s founders, Tony Rosinol and Bernard Aceituno, will join Asana as part of the acquisition.

Asana framed the acquisition as part of its broader AI pivot, in which it seeks to build its platform into “the operating system for human-agent teams.”

The announcement was announced Thursday afternoon to coincide with Asana’s earnings and investor call.

Built as an AI workflow-automation system, StackAI designs agents to operate within existing business systems, pulling in data from systems like Salesforce, Slack, and Gsuite. Part of Y Combinator’s Winter ’23 cohort, the company has faced fierce competition from automation tools like Zapier as well as AI labs like OpenAI and Anthropic.

StackAI had raised just under $20 million, according to PitchBook data, with most of it coming in a recent $16 million Series A round. That round included funding from Gradient, Epakon Capital, Lobby VC, LifeX Ventures, and Vercel CEO Guillermo Rauch.

While users are likely most familiar with Asana’s work management system, the company has released a number of AI-oriented products in recent years, most notably the AI Studio automation builder and AI Teammates series of pre-built agents. While equivalent tools are available from major labs, Asana sees its deep integration into existing corporate workflows as a key advantage, allowing it to distill context and training data that would otherwise be unavailable.

Asana has struggled on public markets during the AI era, losing more than half its market cap value since the introduction of ChatGPT — a spiral that grew worse with the departure of founder Dustin Moskovitz as CEO last March. But revenue has continued to grow steadily, and the new leadership is confident that its human-agent products will enable it to rebound.

“This acquisition accelerates our roadmap and takes us into the next phase of human-agent work,” said CEO Dan Rogers in a statement. “We’re already seeing real momentum with AI Teammates and AI Studio … StackAI now lets them go further, agentifying the most complex business processes end-to-end.”

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Russell Brandom has been covering the tech industry since 2012, with a focus on platform policy and emerging technologies. He previously worked at The Verge and Rest of World, and has written for Wired, The Awl and MIT’s Technology Review. He can be reached at [email protected] or on Signal at 412-401-5489.

Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?Asana NYSE: ASAN reported fiscal first-quarter revenue that exceeded its guidance range and said customer retention, expansion activity and adoption of its artificial intelligence products improved during the period.

Chief Executive Officer Dan Rogers said the company generated revenue of $205.1 million in the first quarter of fiscal 2027, up 9.5% from a year earlier. He said non-GAAP operating margin expanded to 11.5%, an improvement of 720 basis points year over year, reflecting “continued progress in driving both growth and operating efficiency across the business.”

Get Asana alerts:

How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?Rogers said the company saw positive trends in customer retention and expansion, with overall in-quarter net retention improving for the fourth consecutive quarter to 97%. He said the improvement was broad-based across gross retention and expansion activity, supported by healthier seat adoption, improved customer engagement and early traction from Asana’s AI products.

AI Products Drive Expansion Activity Rogers said Asana’s strategy is to become “the operating system for human agent teams,” positioning the company around workflows where employees and AI agents collaborate on business-critical processes. He said the company believes many organizations have experienced personal productivity gains from AI chatbots but have not yet translated those gains into broader team or enterprise productivity.

E-Commerce Wars: Asana and Monday.com Battle for the Top SpotThe company highlighted growing adoption of AI Studio, which Rogers said became generally available roughly a year ago. AI Studio is used to automate repeatable work such as intake, classification, routing, quality checks and reporting. Rogers said early data shows customers adopting AI Studio have higher retention and stronger net revenue retention than the broader customer base, with the primary driver being seat expansion rather than lower churn alone.

During the quarter, Rogers said the number of customers spending more than $100,000 annually on AI Studio nearly doubled. In the question-and-answer session, Chief Financial Officer Aziz Megji clarified that those customers were spending more than $100,000 on the AI Studio SKU itself, excluding their core Asana seat spend.

Rogers also discussed AI Teammates, shared AI agents assigned to projects that work alongside employees within Asana’s Work Graph. He said paid conversion from the beta cohort has been strong and that tasks involving AI Teammates are completed nearly nine times faster. Asana said AI product bookings represented 17% of net new annual recurring revenue in the first quarter, ahead of its full-year target of 15%.

StackAI Acquisition Expands AI Workflow Ambitions Asana announced the acquisition of StackAI, a privately held AI software company that offers a no-code AI workflow platform for designing, testing, deploying and governing custom AI agents and intelligent automations. Rogers said StackAI extends Asana’s AI Studio capabilities by enabling workflows across enterprise systems such as CRMs, ERPs, databases, support systems, contracts and custom infrastructure.

Rogers said StackAI accelerates Asana’s roadmap by more than a year. In response to a question from Robert Oliver of Baird, Rogers said customers had been asking to extend AI Studio workflows into third-party systems, and StackAI already had demonstrated traction in complex operating environments, including regulated industries.

Megji said the transaction includes approximately $75 million in upfront cash consideration, along with an equity-based earn-out opportunity. He said the acquisition adds about 50 employees across engineering and AI-focused go-to-market functions. After adjusting for the deal, Megji said Asana would have more than $350 million in cash equivalents and marketable securities remaining on its balance sheet, including an assumption of $3 million of cash on StackAI’s balance sheet.

Customer Metrics and Vertical Trends Improve Megji said Asana ended the quarter with 26,103 “core customers,” defined as customers spending $5,000 or more on an annualized basis. Revenue from core customers grew 10% year over year and represented 76% of total revenue. The company had 817 customers spending $100,000 or more on an annualized basis, up 12% year over year.

Overall dollar-based net retention was 96%, while core customer net retention was 97%. Among customers spending $100,000 or more, net retention was 96%. Megji noted that these figures are trailing four-quarter averages and therefore lag more recent trends.

Rogers said the technology sector returned to positive year-over-year growth for the first time in eight quarters, aided by adoption across multiple products. He cited CoreWeave and Epson as customers that expanded with additional seats and AI products during the quarter. Megji said the improvement in tech was primarily driven by expansion, including add-on AI Studio and AI Teammates adoption, as well as seat expansion and improving retention.

Growth in non-technology sectors continued to outpace overall company growth, according to Rogers. He said international revenue rose 12% year over year, led by EMEA and APAC, and noted new customers including a British athletic apparel brand and IKEA Australia.

Profitability, Cash Flow and Buybacks Megji said Asana’s non-GAAP gross margin was 88%. Research and development expenses were $47.5 million, or 23% of revenue, while sales and marketing expenses were $83.5 million, or 41% of revenue. General and administrative expenses were $26.7 million, or 13% of revenue.

Non-GAAP net income was $24.4 million, or $0.10 per diluted share. Megji said profitability improvements were driven by operating leverage, disciplined spending, infrastructure and cloud cost optimization, and headcount discipline as the company uses AI across internal workflows.

Asana ended the quarter with $424.6 million in cash equivalents and marketable securities. Remaining performance obligations were $518.1 million, up 23% year over year, while current remaining performance obligations grew 18% year over year. Adjusted free cash flow was $34.4 million, or 17% of revenue.

The company repurchased $45 million of Class A common stock during the quarter, buying 7.4 million shares at an average price of $6.11 per share. Megji said Asana had roughly $155 million remaining under its current repurchase authorization as of April 30.

Guidance Includes StackAI Contribution For the second quarter of fiscal 2027, Asana expects revenue of $213 million to $215 million, representing growth of 8.2% to 9.2% year over year. The outlook includes an expected StackAI contribution of about 50 basis points to growth. The company expects non-GAAP operating income of $18 million to $20 million and non-GAAP net income of $0.08 to $0.09 per share.

For the full fiscal year, Asana expects revenue of $855.5 million to $863.5 million, also representing growth of 8.2% to 9.2%. The full-year outlook includes the first-quarter outperformance and an expected StackAI contribution of approximately 50 basis points to growth. Asana expects a full-year non-GAAP operating margin of at least 9.75% and non-GAAP net income of $0.37 per share.

Megji said the company’s outlook continues to assume roughly a two-point drag on annual recurring revenue growth from its product-led growth motion, only modest improvement in net retention over the year, and AI product bookings contributing about 15% of net new ARR in fiscal 2027. He said Asana plans to provide a more comprehensive update on AI product contribution during its second-quarter call.

About Asana NYSE: ASANAsana, Inc NYSE: ASAN is a leading provider of work management and collaboration software designed to help teams organize, track and manage their work. Founded in 2008 by Dustin Moskovitz and Justin Rosenstein, Asana's platform enables users to create projects, assign tasks, set deadlines and visualize progress across diverse workflows. The company's cloud-based solution includes customizable project templates, timeline views, boards and automated rules that streamline routine processes and reduce manual effort.

Built for both small teams and large enterprises, Asana supports integrations with a wide array of third-party applications, including communication tools, file-sharing services and DevOps platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Asana Right Now?Before you consider Asana, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Asana wasn't on the list.

While Asana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

Asana, Inc. (ASAN) Q1 2027 Earnings Call Transcript